EA201990604A1 - Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders - Google Patents

Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders

Info

Publication number
EA201990604A1
EA201990604A1 EA201990604A EA201990604A EA201990604A1 EA 201990604 A1 EA201990604 A1 EA 201990604A1 EA 201990604 A EA201990604 A EA 201990604A EA 201990604 A EA201990604 A EA 201990604A EA 201990604 A1 EA201990604 A1 EA 201990604A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complement
factor
heteroaryl
aryl
treatment
Prior art date
Application number
EA201990604A
Other languages
Russian (ru)
Other versions
EA038607B1 (en
Inventor
Венкат Рао Гадхачанда
Цюпин Ван
Годвин Пэйс
Акихиро Хашимото
Давей Чэнь
Сянчжу Ван
Атул Агарвал
Милинд Дешпанде
Авинаш С. Фадке
Джейсон Аллан Вайлс
Original Assignee
Ачиллион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ачиллион Фармасьютикалс, Инк. filed Critical Ачиллион Фармасьютикалс, Инк.
Publication of EA201990604A1 publication Critical patent/EA201990604A1/en
Publication of EA038607B1 publication Critical patent/EA038607B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Заявлены соединения, способы применения и способы получения ингибиторов фактора D комплемента, включающих формулу I, или их фармацевтически приемлемая соль, или их композиция, где Rили Rна группе A представляет собой арил, гетероарил или гетероцикл (R). Описанные в настоящем документе ингибиторы воздействуют на фактор D и ингибируют или регулируют каскад комплемента в ранней и существенной точке альтернативного пути комплемента, и снижают способность фактора D модулировать классический и лектиновый пути комплемента. Описанные в настоящем документе ингибиторы фактора D способны снижать чрезмерную активацию комплемента, которая связана с определенными аутоиммунными, воспалительными и нейродегенеративными заболеваниями, а также ишемически-реперфузионными повреждениями и раком.The claimed compounds, methods of use and methods for the preparation of inhibitors of factor D complement, including formula I, or a pharmaceutically acceptable salt, or a composition thereof, where R or R on group A is aryl, heteroaryl or heterocycle (R). The inhibitors described herein act on factor D and inhibit or regulate the complement cascade at an early and significant point in the alternative complement pathway and reduce the ability of factor D to modulate the classical and lectin complement pathways. The factor D inhibitors described herein are capable of reducing excessive complement activation, which is associated with certain autoimmune, inflammatory and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

EA201990604A 2014-09-05 2015-02-25 Aryl, heteroaryl and heterocyclic compounds for treating complement-mediated disorders EA038607B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046783P 2014-09-05 2014-09-05

Publications (2)

Publication Number Publication Date
EA201990604A1 true EA201990604A1 (en) 2020-01-09
EA038607B1 EA038607B1 (en) 2021-09-22

Family

ID=69374504

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202191781A EA202191781A1 (en) 2014-09-05 2015-02-25 ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF DISORDERS MEDIED BY THE COMPLETE
EA201990604A EA038607B1 (en) 2014-09-05 2015-02-25 Aryl, heteroaryl and heterocyclic compounds for treating complement-mediated disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202191781A EA202191781A1 (en) 2014-09-05 2015-02-25 ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF DISORDERS MEDIED BY THE COMPLETE

Country Status (1)

Country Link
EA (2) EA202191781A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2119703T3 (en) * 2007-01-15 2013-01-14 Santen Pharmaceutical Co Ltd New indole derivative with inhibitory effect on I-B kinase.
SG191844A1 (en) * 2011-01-04 2013-08-30 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9056874B2 (en) * 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof

Also Published As

Publication number Publication date
EA038607B1 (en) 2021-09-22
EA202191781A1 (en) 2021-09-03

Similar Documents

Publication Publication Date Title
EA201691730A1 (en) ARYL, HETEROAARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISTRESSED-MEDIATED COMPLETE
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201890338A1 (en) OXADIAZOLIC DERIVATIVES SUITABLE AS HDAC INHIBITORS
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201890594A1 (en) Aryl, Heteroaryl, and Heterocyclic Compounds for the Treatment of Disorders
EA201691516A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201890308A1 (en) SUBSTITUTED ASO COMPOUNDS AS IRAK-4 INHIBITORS
EA201600234A1 (en) 1,3,4-OXADIAZOLE AND 1,3,4-TIADIAZOLE DERIVATIVES AS AN IMMUNOMODULATOR
EA201790528A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201691803A1 (en) HUMAN PLASMA KALLIKREIN INHIBITORS
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201600235A1 (en) CYCLIC PEPTIDOMYMETIC COMPOUNDS AS IMMUNOMODULATORS
EA201591753A1 (en) 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS
EA202090291A3 (en) BIPIRAZOLE DERIVATIVES AS JAK INHIBITORS
EA201691354A1 (en) THERAPEUTIC INHIBITIVE COMPOUNDS
EA201790088A1 (en) SYK INHIBITORS
EA201591745A1 (en) 3-PYRIMIDIN-4-IL-OXAZOZOLIDIN-2-ONE AS INHIBITORS MUTANT IDH
EA201591296A1 (en) PHTHALASINONES AND ISOHINOLINONES AS ROCK INHIBITORS
EA201790599A1 (en) COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA201791293A1 (en) SITE SPECIFIC DOSING OF BTK INHIBITOR
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS